Pembrolizumab for Early Triple-Negative Breast Cancer

Abstract

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).

Keywords

Affiliated Institutions

• Vall d'Hebron Institute of Oncology
• Champalimaud Foundation PT
• Texas Oncology US
• Yale Cancer Center US
• National University of Singapore SG
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• Westmead Institute AU
• Helios Hospital Berlin-Buch DE
• Kliniken Essen-Mitte DE
• Cedars-Sinai Medical Center US
• Samsung Medical Center KR
• Ludwig-Maximilians-Universität München DE
• Karolinska Institutet SE
• Sapporo National Hospital JP
• Universitätsklinikum Erlangen DE
• Baylor University Medical Center US
• Karolinska University Hospital SE
• Queen Mary University of London GB
• National Hospital Organization Hokkaido Medical Center JP
• National Cancer Centre Singapore SG
• Comprehensive Cancer Center Erlangen DE
• The University of Sydney AU
• Westmead Hospital AU
• Philipps University of Marburg DE
• Sungkyunkwan University KR
• Breast Center CH

Related Publications